Cargando…
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018417/ https://www.ncbi.nlm.nih.gov/pubmed/35260843 http://dx.doi.org/10.1038/s41591-022-01771-w |
| _version_ | 1784689047456710656 |
|---|---|
| author | Kjeldsen, Julie Westerlin Lorentzen, Cathrine Lund Martinenaite, Evelina Ellebaek, Eva Donia, Marco Holmstroem, Rikke Boedker Klausen, Tobias Wirenfeldt Madsen, Cecilie Oelvang Ahmed, Shamaila Munir Weis-Banke, Stine Emilie Holmström, Morten Orebo Hendel, Helle Westergren Ehrnrooth, Eva Zocca, Mai-Britt Pedersen, Ayako Wakatsuki Andersen, Mads Hald Svane, Inge Marie |
| author_facet | Kjeldsen, Julie Westerlin Lorentzen, Cathrine Lund Martinenaite, Evelina Ellebaek, Eva Donia, Marco Holmstroem, Rikke Boedker Klausen, Tobias Wirenfeldt Madsen, Cecilie Oelvang Ahmed, Shamaila Munir Weis-Banke, Stine Emilie Holmström, Morten Orebo Hendel, Helle Westergren Ehrnrooth, Eva Zocca, Mai-Britt Pedersen, Ayako Wakatsuki Andersen, Mads Hald Svane, Inge Marie |
| author_sort | Kjeldsen, Julie Westerlin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9018417 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90184172022-04-29 Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma Kjeldsen, Julie Westerlin Lorentzen, Cathrine Lund Martinenaite, Evelina Ellebaek, Eva Donia, Marco Holmstroem, Rikke Boedker Klausen, Tobias Wirenfeldt Madsen, Cecilie Oelvang Ahmed, Shamaila Munir Weis-Banke, Stine Emilie Holmström, Morten Orebo Hendel, Helle Westergren Ehrnrooth, Eva Zocca, Mai-Britt Pedersen, Ayako Wakatsuki Andersen, Mads Hald Svane, Inge Marie Nat Med Author Correction Nature Publishing Group US 2022-03-08 2022 /pmc/articles/PMC9018417/ /pubmed/35260843 http://dx.doi.org/10.1038/s41591-022-01771-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Kjeldsen, Julie Westerlin Lorentzen, Cathrine Lund Martinenaite, Evelina Ellebaek, Eva Donia, Marco Holmstroem, Rikke Boedker Klausen, Tobias Wirenfeldt Madsen, Cecilie Oelvang Ahmed, Shamaila Munir Weis-Banke, Stine Emilie Holmström, Morten Orebo Hendel, Helle Westergren Ehrnrooth, Eva Zocca, Mai-Britt Pedersen, Ayako Wakatsuki Andersen, Mads Hald Svane, Inge Marie Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma |
| title | Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma |
| title_full | Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma |
| title_fullStr | Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma |
| title_full_unstemmed | Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma |
| title_short | Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma |
| title_sort | author correction: a phase 1/2 trial of an immune-modulatory vaccine against ido/pd-l1 in combination with nivolumab in metastatic melanoma |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018417/ https://www.ncbi.nlm.nih.gov/pubmed/35260843 http://dx.doi.org/10.1038/s41591-022-01771-w |
| work_keys_str_mv | AT kjeldsenjuliewesterlin authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT lorentzencathrinelund authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT martinenaiteevelina authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT ellebaekeva authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT doniamarco authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT holmstroemrikkeboedker authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT klausentobiaswirenfeldt authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT madsencecilieoelvang authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT ahmedshamailamunir authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT weisbankestineemilie authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT holmstrommortenorebo authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT hendelhellewestergren authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT ehrnrootheva authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT zoccamaibritt authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT pedersenayakowakatsuki authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT andersenmadshald authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma AT svaneingemarie authorcorrectionaphase12trialofanimmunemodulatoryvaccineagainstidopdl1incombinationwithnivolumabinmetastaticmelanoma |